1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Texas >
  6. AREVA Med Acquires Macrocyclics

M&A Deal Summary

AREVA Med Acquires Macrocyclics

On October 20, 2011, AREVA Med acquired life science company Macrocyclics

Acquisition Highlights
  • This is AREVA Med’s 1st transaction in the Life Science sector.
  • This is AREVA Med’s 1st transaction in the United States.
  • This is AREVA Med’s 1st transaction in Texas.

M&A Deal Summary
Date 2011-10-20
Target Macrocyclics
Sector Life Science
Buyer(s) AREVA Med
Deal Type Add-on Acquisition

Target

Macrocyclics

Dallas, Texas, United States
Macrocyclics, Inc. is a provider of chelators*, chemical agents that allow for the attachment of antibodies or proteins with radioactive isotopes for the development of powerful nuclear medical treatments targeted against aggressive types of cancer.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

AREVA Med

Bethesda, Maryland, United States
Category Company
Founded 2009
Sector Life Science
DESCRIPTION

AREVA Med LLC is a developer of innovative methods for producing lead-212 (212Pb), a rare radioactive isotope at the heart of promising research projects in nuclear medicine to develop new treatments against cancer.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Texas M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2011 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal